Last reviewed · How we verify
NCT05162677
Prophylactic Mastectomy: Prospective Evaluation of the Correlation Between Skin Flap Thickness, Residual Glandular Tissue and Skin Necrosis by Imaging and Clinical Examination
trial in Prophylactic Mastectomy in 45 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Umeå University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 45 |
| Start date | 25 August 2022 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Sweden |
Conditions studied
- Prophylactic Mastectomy — all drugs for Prophylactic Mastectomy →
Sponsor
Umeå University
Who can join
Adults 18 to 74, female only, with Prophylactic Mastectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast cancer is the most common form of cancer among women. Five to ten percent of all breast cancers are due to hereditary factors, with pathogenic variants in the breast cancer genes BRCA1/2 accounting for 2-5% of all breast cancer. Women with pathogenic variants in BRAC1/2 and other pathogenic gene mutations leading to an increased risk of breast cancer can undergo prophylactic mastectomy, reducing the risk of breast cancer up to 90%. Among women who have undergone prophylactic mastectomy, 1-1,9% are diagnosed with breast cancer, but little is known about the correlation between residual glandular tissue and skin flap thickness, as well as the oncological risk of residual glandular tissue. Furthermore, there is a balance between how much subcutaneous tissue should be resected to achieve maximal reduction of glandular tissue, while leaving viable skin flaps. In addition, there are established surveillance guidelines for women with pathogenic variants in BRCA1/2 who do not undergo risk-reducing surgery, but no published consensus or guidelines regarding appropriate medical follow-up for those who opt for prophylactic mastectomy. The aim of this study is to investigate the correlation between skin flap thickness, residual glandular tissue and skin flap necrosis following prophylactic mastectomy in women with results from postoperative magnetic resonance tomography, ultrasound and physical examination, as well as evaluate patient satisfaction and quality of life pre- and postoperatively with different questionnaires.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05162677
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prophylactic Mastectomy
Currently open trials in the same condition.
- NCT04537312 — Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM) · NA · active not recruiting
Other Umeå University trials
Trials by the same sponsor.
- NCT07407946 — Blended Trauma-Focused Cognitive Behavioral Therapy With Compassion · NA · recruiting
- NCT07346820 — VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation · not yet recruiting
- NCT07417358 — Single-Stapled Technique for Colorectal Anastomosis · recruiting
- NCT07316426 — Preoptimisation in Ventral Hernia Surgery · NA · recruiting
- NCT07170722 — Sub-threshold DRG Stimulation vs Sham in Established Responders · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05162677 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Umeå University
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162677.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing